ABL Bio Receives Upfront Payment and Equity Investment from Lilly for Grabody Platform
ABL Bio has secured a total of USD 55 million in funding from Lilly, including a USD 40 million upfront payment and a USD 15 million equity investment, under a license, research and collaboration agreement to advance R&D and expand indications for its Grabody platform.
HSR Act | 26/12/2025 | By News Bureau
Novartis Announces Expiration of HSR Waiting Period of Regulus Therapeutics Tender Offer
Novartis announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the HSR Act), in connection with Novartis’ previously announced tender offer to acquire all of the outstanding shares of common stock.
HSR Act | 24/06/2025 | By Darshana | 117
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy